ArticleNature communications2022
Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Single cell profiling reveals malignant states and immune landscapes in PCNSL and systemic DLBCL.iScience · 2026Article
- CD39/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer.Cancer immunology, immunotherapy : CII · 2026Article
- The expression of CD39 on NK cells relates to poor HIV-1 suppression in treatment-naïve HIV-1-infected individuals: Association with elevated IL-10 secretion and TIGIT co-expression.Virologica Sinica · 2026Article
- Single-cell transcriptome analysis reveals DNMT1Journal of translational medicine · 2026Article
- Disrupting USP14-mediated PARP1 dynamics reinstates MIC-A/B-driven antigen-independent CD8Science advances · 2026Article
- Regulatory T cells in the bladder cancer tumor microenvironment: mechanisms of immune suppression and therapeutic opportunities.Frontiers in molecular biosciences · 2026Review
- Glycolysis-mediated H3K18la modifications drive aggressive bladder cancer through metabolic and epigenetic reprogramming.Frontiers in immunology · 2026Article
- Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor.International journal of biological sciences · 2026Article
- EGFR-targeted photoimmunotherapy and its association with the immune microenvironment in locoregional recurrent head and neck squamous cell carcinoma.Frontiers in immunology · 2026Article
- Pan-cancer neural regulation pattern with implications for patient stratification and immunotherapy.Molecular therapy. Nucleic acids · 2025Article
- Single-cell sequencing in bladder cancer: new insights from tumor cell diversity to individualized treatment strategies.Cancer cell international · 2025Review
- CD39 and CD73: biological functions, diseases and therapy.Molecular biomedicine · 2025Review
- Single-cell atlas of the esophageal squamous cell carcinoma immune ecosystem to predict immunotherapy response.Signal transduction and targeted therapy · 2025Article
- Prognostic analysis and immunotherapy prediction based on key receptor-ligand pairs of bladder cancer.Discover oncology · 2025Article
- mRNA-encoded mutant HPV16/18 vaccines promote specific T-cell responses and synergize with anti-PD-1 checkpoint blockade in mediating therapeutic tumor regression in mice.Journal for immunotherapy of cancer · 2025Article
- Article
- Pathway-based cancer transcriptome deciphers a high-resolution intrinsic heterogeneity within bladder cancer classification.Journal of translational medicine · 2025Article
- Targeting CD39 boosts PD-1 blockade antitumor therapeutic efficacy via strengthening CD8 + TILs function and recruiting B cells in cervical cancer.Journal of nanobiotechnology · 2025Article
- RNA‑seq analysis of predictive markers associated with glutamine metabolism in thyroid cancer.Molecular medicine reports · 2025Article
- Causal effects of immune cells on the efficacy and adverse drug reactions of platinum drugs.Acta biochimica et biophysica Sinica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-cell sequencing technologies have noteworthily improved our understanding of the genetic map and molecular characteristics of bladder cancer (BC). Here we identify CD39 as a potential therapeutic target for BC via single-cell transcriptome analysis. In a subcutaneous tumor model and orthotopic bladder cancer model, inhibition of CD39 (CD39i) by sodium polyoxotungstate is able to limit the growth of BC and improve the overall survival of tumor-bearing mice. Via single cell RNA sequencing, we find that CD39i increase the intratumor NK cells, conventional type 1 dendritic cells (cDC1) and CD8 + T cells and decrease the Treg abundance. The antitumor effect and reprogramming of the tumor microenvironment are blockaded in both the NK cells depletion model and the cDC1-deficient Batf3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.